Company Introduction

Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. Insilico Medicine has also published over 100 peer-reviewed papers and has applied for over 25 patents.

Brief description of main products or services 

• Specializes in Target Discovery using multi-omics data
• Designs Novel Molecules for different drug targets
• Predicts clinical trial outcomes
• 8 Internal pre-clinical programs, 1 nearing IND-enabling with novel target, all coming out of the Pharma.AI platform
• Main strengths: Generative Adversarial Networks (GANs) and Deep Reinforcement Learning. 100+ peer-reviewed research papers as Insilico Medicine since 2014
• Insilico is the Originator of the core Generative Artificial Intelligence-based drug discovery technologies, protected by IP
• Fastest drug discovery platform that exists today

(MIT Technology Review Top 10 Breakthroughs of 2020)